Right Brain Bio, Inc.

Right Brain Bio, Inc.

Biotechnology Research

Transforming Parkinson's Disease Treatment

About us

Right Brain Bio uses human intelligence to identify diseases with contradictions or inconsistencies in their foundational assumptions in pursuit of new therapeutic strategies. Our lead product provides dopamine reduction therapy for Parkinson's disease, which is ready to enter Phase 2A clinical trials.

Industry
Biotechnology Research
Company size
1 employee
Type
Privately Held
Founded
2022
Specialties
Parkinson's

Updates

  • Learn about our work to conquer Parkinson’s at https://lnkd.in/eeeyDK7Q

    View profile for Lawrence Rogak, graphic

    Philosopher/ lawyer who wrote the book on New York PIP. No artificial intelligence, ever.

    The marble sculpture of Moses, rendered by Michelangelo between the years 1513 and 1515, exemplifies the remarkable proficiency with which the artist depicts human anatomy. A notable aspect of this work is the representation of a minor muscle in Moses' forearm, which is anatomically engaged solely during the contraction associated with lifting the pinky finger. The visible tension of this muscle in the sculpture serves to underscore Michelangelo's extraordinary attention to anatomical detail and mastery in the medium of marble. And this was accomplished over five hundred years ago.

    • No alternative text description for this image
  • View organization page for Right Brain Bio, Inc., graphic

    32 followers

    A 1-minute pitch to support a transformative, contrarian, paradigm-shifting treatment for Parkinson's disease.

    View profile for Jonathan Sackner-Bernstein, MD, graphic

    Transforming Parkinson’s Disease Treatment. Track Record as Innovator. Experience at FDA and DARPA. "Worthy 100" (2023).

    What's the best way to pitch to investors? Some say no more than 10 slides. Others recommend the science comes first. We've heard that we must include uses of funds. The list of requests goes on and on. Here's a thought. What if we presented the problem, our discovery that addresses the problem and then the possibilities for impact? Here's a 1-minute stand-alone pitch. We can look at slides, but this is the message. • The problem with Parkinson's disease is that 𝗻𝗼 𝗼𝗻𝗲 𝗴𝗲𝘁𝘀 𝗯𝗲𝘁𝘁𝗲𝗿. • The state–of–the–art 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗶𝘀 𝗽𝗮𝗹𝗹𝗶𝗮𝘁𝗶𝘃𝗲 and unchanged since proposed in the 1960s. • We 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝗲𝗱 the reason these treatments don't work. And then we 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝗲𝗱 a treatment that will. • In contrast to the typical scientific breakthrough, we are developing a therapy that is 𝗻𝗼𝘁 𝗮𝗻 𝗶𝗻𝗰𝗿𝗲𝗺𝗲𝗻𝘁𝗮𝗹 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 – it will completely change the landscape. • We're talking about a 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲, 𝗽𝗮𝗿𝗮𝗱𝗶𝗴𝗺–𝘀𝗵𝗶𝗳𝘁𝗶𝗻𝗴, 𝗰𝗼𝗻𝘁𝗿𝗮𝗿𝗶𝗮𝗻 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵 supported by experimental data in 9 models of disease, for which the FDA agreed we are ready to launch Phase 2 trials. • How would you feel to 𝗯𝗲 𝗽𝗮𝗿𝘁 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗼𝗻𝗰𝗲 𝗶𝗻 𝗮 𝗹𝗶𝗳𝗲𝘁𝗶𝗺𝗲 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 to permanently change the understanding of a common, debilitating, neurodegenerative disease, in so doing, transform the lives of millions? Where are the early-adopters, the risk-takers and/or those with capital to invest who have been (or are) affected by Parkinson's? The Michael J. Fox Foundation for Parkinson's Research Parkinson's Foundation Parkinson's UK Critical Path Institute (C-Path) Parkinson's Disease (PD) Parkinson's (PD)

  • View organization page for Right Brain Bio, Inc., graphic

    32 followers

    Parkinson's causes more problems than moving slowly. Anyone satisfied with current therapeutics for the disease, including those treating complications, needs to realize that nothing works well enough. Let's challenge first principles, get creative and focus on exploring new models of disease. Tomorrow our weekly newsletter will dig in to the science underlying dyskinesia - uncontrollable movements - as the first step towards figuring out new approaches. The Michael J. Fox Foundation for Parkinson's Research Parkinson's Foundation Cure Parkinson's Critical Path Institute (C-Path)

    View profile for Jonathan Sackner-Bernstein, MD, graphic

    Transforming Parkinson’s Disease Treatment. Track Record as Innovator. Experience at FDA and DARPA. "Worthy 100" (2023).

    𝗜𝘀 𝗱𝘆𝘀𝗸𝗶𝗻𝗲𝘀𝗶𝗮 𝗰𝗮𝘂𝘀𝗲𝗱 𝗯𝘆 𝗲𝘅𝗰𝗲𝘀𝘀𝗶𝘃𝗲𝗹𝘆 𝗵𝗶𝗴𝗵 𝗽𝗲𝗮𝗸 𝗹𝗲𝘃𝗲𝗹𝘀 𝗼𝗳 𝗱𝗼𝗽𝗮𝗺𝗶𝗻𝗲? 𝗡𝗼. There is not a particular clinical or laboratory study that proves this, but the data are pretty strong that support this as fact. If you don't think dyskinesia is important enough for our focus, please watch at least the first 30 seconds of this youtube video. Dyskinesia is a major problem. https://lnkd.in/eQhqHru4 We now have two sets of clinical trials showing how to eliminate peak drug levels - infusion using intestinal gel (Duopa) and by subcutaneous route (ND0612). Each shows itself capable of eliminating peaks. But while there are improvements, neither one comes close to eliminating dyskinesia or troublesome dyskinesia. So these approaches are important to palliate symptoms, but we owe people with Parkinson's way more than palliation. I provide more detail in my weekly newsletter to publish tomorrow at: ParkinsonsDisease.blog It's great to be offer patients with some relief from what can be disabling motor dysfunction, but at some point we need to realize that fine-tuning levodopa delivery will not fix the problem of dyskinesia. Read more on the blog. The Michael J. Fox Foundation for Parkinson's Research Parkinson's Foundation #parkinsons

    "Why Not" Wednesdays: In Pursuit of How to Conquer Parkinson's

    "Why Not" Wednesdays: In Pursuit of How to Conquer Parkinson's

    parkinsonsdisease.blog

  • View organization page for Right Brain Bio, Inc., graphic

    32 followers

    𝗦𝗵𝗼𝘂𝗹𝗱 𝘄𝗲 𝗯𝗲𝗹𝗶𝗲𝘃𝗲 𝘁𝗵𝗮𝘁 𝗹𝗲𝘃𝗼𝗱𝗼𝗽𝗮 𝘄𝗼𝗿𝗸𝘀 𝗯𝘆 𝗿𝗲𝗽𝗹𝗮𝗰𝗶𝗻𝗴 𝗱𝗼𝗽𝗮𝗺𝗶𝗻𝗲 𝗶𝗻𝘀𝗶𝗱𝗲 𝘁𝗵𝗲 𝗻𝗲𝘂𝗿𝗼𝗻𝘀? 𝗢𝗿 𝗰𝗼𝘂𝗹𝗱 𝗶𝘁 𝘄𝗼𝗿𝗸 𝗯𝘆 𝘀𝗲𝗻𝘀𝗶𝘁𝗶𝘇𝗶𝗻𝗴 𝗿𝗲𝗰𝗲𝗽𝘁𝗼𝗿𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗼𝘂𝘁𝘀𝗶𝗱𝗲? The answers with graphic explanations are available at: https://lnkd.in/enf6QbZc I was taught that levodopa works by crossing the blood-brain barrier and is then taken up by neurons. Inside the neurons, tyrosine hydroxylase converts it to dopamine which is then stored within the vesicles to prevent formation of toxic metabolites. When the neuron is activated, vesicles move to the synapse, fuse with the membrane and release dopamine to activate the postsynaptic receptors. But there is a problem with this view. Much of that activity depends on an ample supply of energy (ATP and GTP) which the neurons and their mitochondria can't make owing to the pathology of Parkinson's. This energy crisis for dopaminergic neurons in Parkinson's means there must be a different mechanism of action for levodopa. In this week's newsletter, I discuss this in more detail, including explanation of my first GIFs (below). https://lnkd.in/enf6QbZc Given that dopamine receptors are G-protein coupled receptors, it's much more likely that levodopa works by increasing the sensitivity of these postsynaptic dopamine receptors. And G-protein couple receptor physiology also explains why levodopa benefit wanes over time - the initial increase in receptor sensitivity eventually shifts to receptor desensitizing. The bottom line? 𝘛𝘩𝘦𝘳𝘦 𝘪𝘴 𝘮𝘶𝘤𝘩 𝘸𝘦 𝘣𝘦𝘭𝘪𝘦𝘷𝘦 𝘵𝘰 𝘣𝘦 𝘵𝘳𝘶𝘦 𝘢𝘯𝘥 𝘵𝘩𝘢𝘵 𝘸𝘦 𝘢𝘤𝘤𝘦𝘱𝘵 𝘢𝘴 𝘵𝘳𝘶𝘦. 𝘉𝘶𝘵 𝘴𝘰𝘮𝘦 𝘰𝘧 𝘵𝘩𝘦𝘴𝘦 𝘥𝘰𝘤𝘵𝘳𝘪𝘯𝘦𝘴 𝘴𝘵𝘢𝘳𝘵 𝘵𝘰 𝘭𝘰𝘰𝘬 𝘢 𝘭𝘪𝘵𝘵𝘭𝘦 𝘴𝘩𝘢𝘬𝘺 𝘸𝘩𝘦𝘯 𝘨𝘰𝘪𝘯𝘨 𝘣𝘢𝘤𝘬 𝘵𝘰 𝘵𝘩𝘦 𝘣𝘢𝘴𝘪𝘤𝘴 𝘢𝘯𝘥 𝘢𝘱𝘱𝘭𝘺𝘪𝘯𝘨 𝘵𝘰𝘥𝘢𝘺'𝘴 𝘬𝘯𝘰𝘸𝘭𝘦𝘥𝘨𝘦-𝘣𝘢𝘴𝘦. The other lesson from this analysis? Just because levodopa helps people with Parkinson's does not automatically mean that the disease is one of dopamine deficiency. In fact, we expect to demonstrate in our first clinical trial that this is not the case. To the dopaminergic neurons, Parkinson's is a disease of dopamine excess. 𝙎𝙞𝙜𝙣 𝙪𝙥 𝙛𝙤𝙧 𝙢𝙮 𝙬𝙚𝙚𝙠𝙡𝙮 𝙣𝙚𝙬𝙨𝙡𝙚𝙩𝙩𝙚𝙧 𝙖𝙩 𝙋𝙖𝙧𝙠𝙞𝙣𝙨𝙤𝙣𝙨𝘿𝙞𝙨𝙚𝙖𝙨𝙚.𝙗𝙡𝙤𝙜 𝙝𝙩𝙩𝙥𝙨://𝙥𝙖𝙧𝙠𝙞𝙣𝙨𝙤𝙣𝙨𝙙𝙞𝙨𝙚𝙖𝙨𝙚.𝙗𝙡𝙤𝙜 The Michael J. Fox Foundation for Parkinson's Research Parkinson's UK Parkinson's Foundation Critical Path Institute (C-Path)

    • No alternative text description for this image
    • No alternative text description for this image
  • View organization page for Right Brain Bio, Inc., graphic

    32 followers

    𝗧𝗵𝗲 𝗻𝗲𝘅𝘁 𝘀𝘁𝗲𝗽? 𝗜𝗱𝗲𝗻𝘁𝗶𝗳𝘆 𝗮𝗻𝗱 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗻𝗼𝘃𝗲𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀. Diagnostics are so, so important. But without therapeutic options... Would it make sense to increase the The Michael J. Fox Foundation for Parkinson's Research Therapeutic Pipeline grant opportunity, either in number awarded or maximum amount available? Two million dollars over two years is a lot of money, but it does not seem that this will necessarily be enough when figuring in manufacturing costs and the kind of oversight necessary for the FDA to accept the data as a step towards the market. Let's keep the focus on Parkinson's - including therapeutics. 𝙎𝙞𝙜𝙣 𝙪𝙥 𝙛𝙤𝙧 𝙢𝙮 𝙬𝙚𝙚𝙠𝙡𝙮 𝙣𝙚𝙬𝙨𝙡𝙚𝙩𝙩𝙚𝙧 𝙖𝙩 𝙋𝙖𝙧𝙠𝙞𝙣𝙨𝙤𝙣𝙨𝘿𝙞𝙨𝙚𝙖𝙨𝙚.𝙗𝙡𝙤𝙜 https:parkinsonsdisease.blog #parkinsons #parkinsonsdisease The Michael J. Fox Foundation for Parkinson's Research Parkinson's Foundation Parkinson's UK Critical Path Institute (C-Path)

    Just over a year ago, there was a major breakthrough in Parkinson’s disease (PD) research – the discovery of a tool that could detect abnormal alpha-synuclein protein in the spinal fluid of people living with PD even before onset of symptoms. In our recent “Parkinson’s Science POV” podcast episode, MJFF’s Maggie McGuire Kuhl, vice president of research engagement leads a discussion with Brian Fiske, PhD and Mark Frasier, PhD, MJFF co-chief science officers. They discuss the ways the biomarker discovery helps reveal connections with other brain diseases and holds the promise to make clinical trials cheaper, faster and more effective. Listen now: https://bit.ly/3LoS0FK

  • View organization page for Right Brain Bio, Inc., graphic

    32 followers

    𝗔 𝗺𝗲𝘀𝘀𝗮𝗴𝗲 𝗳𝗼𝗿 𝘁𝗵𝗼𝘀𝗲 𝘄𝗶𝘁𝗵 𝗣𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻'𝘀 𝗮𝗻𝗱 𝗮𝗻𝘆𝗼𝗻𝗲 𝗲𝗹𝘀𝗲 𝘄𝗵𝗼 𝗴𝗼𝗲𝘀 𝗼𝘂𝘁𝘀𝗶𝗱𝗲. Wear sunblock to prevent skin cancer and get checked out by your dermatologist to find early problems.

    View profile for Jonathan Sackner-Bernstein, MD, graphic

    Transforming Parkinson’s Disease Treatment. Track Record as Innovator. Experience at FDA and DARPA. "Worthy 100" (2023).

    𝗣𝗲𝗼𝗽𝗹𝗲 𝘄𝗶𝘁𝗵 𝗣𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻'𝘀 𝗮𝗿𝗲 𝗮𝘁 𝗿𝗶𝘀𝗸 𝗳𝗼𝗿 𝘀𝗸𝗶𝗻 𝗰𝗮𝗻𝗰𝗲𝗿. 𝗕𝗼𝗼𝗸 𝗮 𝘀𝗸𝗶𝗻 𝗰𝗵𝗲𝗰𝗸 𝗮𝗽𝗽𝗼𝗶𝗻𝘁𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝘆𝗼𝘂𝗿 𝗱𝗲𝗿𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝗶𝘀𝘁 𝗮𝗻𝗱 𝘄𝗲𝗮𝗿 𝘀𝘂𝗻𝗯𝗹𝗼𝗰𝗸.  Parkinson's is associated with an increased risk of melanoma, a skin cancer that can metastasize to vital organs and kill you. While there are great new treatments, prevention is even better. Sign up for my weekly newsletter at ParkinsonsDisease.blog https://lnkd.in/eDnAJM7h #sunblock #skincancer #parkinsons The Michael J. Fox Foundation for Parkinson's Research Parkinson's Foundation Parkinson's UK American Academy of Dermatology

  • View organization page for Right Brain Bio, Inc., graphic

    32 followers

    Does President Biden have Parkinson's (or a Parkinsonian syndrome)? One manifestation of Parkinson's is micrographia, in which the handwriting gets smaller over time. I tried to find images of his handwriting over the years to see if he manifests micrographia, but couldn't find examples other than this image that appears to be on the President's Facebook page. This makes me think he may have that sign of Parkinson's as well. Tell me what you think: Handwriting: https://lnkd.in/eqB7ZuzP

    This content isn’t available here

    Access this content and more in the LinkedIn app

  • View organization page for Right Brain Bio, Inc., graphic

    32 followers

    𝗜𝗳 𝗱𝗼𝗽𝗮𝗺𝗶𝗻𝗲 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗺𝗮𝗸𝗲𝘀 𝘀𝗲𝗻𝘀𝗲 𝘁𝗼 𝘀𝘁𝘂𝗱𝘆, 𝘁𝗵𝗲𝗻 𝘄𝗵𝘆 𝘄𝗼𝘂𝗹𝗱 𝗹𝗲𝘃𝗼𝗱𝗼𝗽𝗮 𝘄𝗼𝗿𝗸? I hear this question a few times a week. And there is an answer, which I started to share in the weekly newsletter this morning (and will complete in Part 2 next week). Hopefully I explain complex pharmacology in a way that makes sense. Read Part 1 at: https://lnkd.in/eqnmpARK 𝙎𝙞𝙜𝙣 𝙪𝙥 𝙛𝙤𝙧 𝙩𝙝𝙚 𝙬𝙚𝙚𝙠𝙡𝙮 𝙣𝙚𝙬𝙨𝙡𝙚𝙩𝙩𝙚𝙧 𝙖𝙩 𝙋𝙖𝙧𝙠𝙞𝙣𝙨𝙤𝙣𝙨𝘿𝙞𝙨𝙚𝙖𝙨𝙚.𝙗𝙡𝙤𝙜 [https://lnkd.in/eeeyDK7Q] The Michael J. Fox Foundation for Parkinson's Research Parkinson's Foundation Parkinson's UK #parkinsons #parkinsonsdisease

    Understanding how levodopa works in Parkinson's

    Understanding how levodopa works in Parkinson's

    parkinsonsdisease.blog

  • View organization page for Right Brain Bio, Inc., graphic

    32 followers

    𝗔 𝗠𝗶𝘀𝘀𝗲𝗱 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝘁𝗼 𝗖𝗼𝗻𝗾𝘂𝗲𝗿 𝗣𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻'𝘀? Who isn't excited about the National Plan to End Parkinson’s Act [https://lnkd.in/dKXDU5XZ]. The law establishes accountability for monitoring progress, with its focus largely on making sure government agencies coordinate work and share progress. It places authority on HHS leadership. We all know the importance of coordinating and sharing lessons in pursuit of any big, difficult goal. Did anyone else find the irony in the nearly simultaneous announcement by ARPA-H about their latest program to promote and support small businesses pursuing innovations for big, difficult goals? They were apparently unaware or indifferent to the National Plan to End Parkinson's Act, as Parkinson's was left off their list. Here is their list [https://lnkd.in/dZ9vv3Y9]: • Ambulatory edema monitor  • Predictive language models for cognitive disability adaptive communication tools  • Cell and gene therapy process analytical technology and quality control testing  • Wearable cell sorting and gene delivery systems  • Precision brain targeting: Non-invasive delivery at the right place and time  • NutriTech: Revolutionizing personalized food as medicine  • Clinic-ready imaging devices and protocols for visualizing the inner ear with high accuracy  • Advanced continuously wearable blood pressure monitoring technologies Am I overlooking something? While the government wants HHS to coordinate the battle against Parkinson's, an Agency within HHS is not interested in battling against Parkinson's? Advanced Research Projects Agency for Health (ARPA-H) The Michael J. Fox Foundation for Parkinson's Research Parkinson's Foundation #parkinsons #parkinsonsdisease 𝙎𝙞𝙜𝙣 𝙪𝙥 𝙛𝙤𝙧 𝙢𝙮 𝙬𝙚𝙚𝙠𝙡𝙮 𝙣𝙚𝙬𝙨𝙡𝙚𝙩𝙩𝙚𝙧 𝙖𝙩 𝙋𝙖𝙧𝙠𝙞𝙣𝙨𝙤𝙣𝙨𝘿𝙞𝙨𝙚𝙖𝙨𝙚.𝙗𝙡𝙤𝙜 [𝙝𝙩𝙩𝙥𝙨://𝙋𝙖𝙧𝙠𝙞𝙣𝙨𝙤𝙣𝙨𝘿𝙞𝙨𝙚𝙖𝙨𝙚.𝙗𝙡𝙤𝙜] 

  • View organization page for Right Brain Bio, Inc., graphic

    32 followers

    𝘽𝙚 𝙤𝙥𝙩𝙞𝙢𝙞𝙨𝙩𝙞𝙘 𝙖𝙗𝙤𝙪𝙩 𝙋𝙖𝙧𝙠𝙞𝙣𝙨𝙤𝙣'𝙨 𝙙𝙞𝙨𝙚𝙖𝙨𝙚. Because any experimental model does not predict a drug's effectiveness in people, rigorous drug development mandates that drugs be tested in multiple models. But even large animal studies lack predictive capability when testing drugs with new mechanisms of action. This may seem pessimistic, but it is realistic. Some models mimic the disease better, but no single model can be confidently relied upon for its predictive power. Think about it this way: in Parkinson's we only know the models that predict effectiveness of dopaminergic therapy, which does not mean such models would predict drugs with different mechanisms of action. So let's look at the data in all the models used to date to test dopamine reduction therapy for Parkinson's. The data from 8 models employed in 9 publications show that dopamine reduction therapy reverses disease pathology. While some may favor one model over another, the consistency is remarkable, and the basis for optimism. Read the full article to learn why you too should be optimistic about Parkinson's at https://lnkd.in/ddPCvpCW 𝗦𝗶𝗴𝗻 𝘂𝗽 𝗳𝗼𝗿 𝗺𝘆 𝘄𝗲𝗲𝗸𝗹𝘆 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿 𝗮𝘁 𝗵𝘁𝘁𝗽𝘀://𝘄𝘄𝘄.𝗣𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻𝘀𝗗𝗶𝘀𝗲𝗮𝘀𝗲.𝗯𝗹𝗼𝗴 The Michael J. Fox Foundation for Parkinson's Research Parkinson's Foundation. Parkinson's Disease (PD) #parkinsons #parkinsonsdisease

    • No alternative text description for this image

Similar pages